Editor - Antoni Stadnicki | Medical University of Silesia | 3937
ISSN: 2161-0479

Journal of Autacoids and Hormones
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Antoni Stadnicki

Antoni Stadnicki
Antoni Stadnicki
Associate Professor
Department of Basic Medical Sciences
Medical University of Silesia
Medical University of Silesia


 Dr. Antoni Stadnicki is an Associate Professor in Department of Basic Medical Sciences in Medical university of Silesia, Poland

Research Interest

By twenty years, my research and clinical interest was mainly involved in inflammatory bowel disease (IBD) and other inflammatory disorders, especially a role of kallikrein – kinin system and coagulation system and related immunological disorders in pathogenesis, complication and treatment of experimental and human IBD. During my appointment in the Department of Gastroenterology, Medical University of Silesia, Katowice, Poland, my investigations focused in a significance of coagulation factor XIII (fibrin stabilization factor) and fibronectin constellation in relation to intestinal bleeding and throboembolic complication in patients with ulcerative colitis (UC) (1,2,3). In the years 1993 – to 1998, I worked in the Sol Sherry Thrombosis Research Center, Temple University Medical School, Philadelphia, USA, since 1996 having Faculty position, doing research manly related to a role of the plasma kallikrein kinin system in experimental models of IBD in collaboration with Prof. DR RB Sartor, from the Department of Digestive Disease and Nutrition, Medical University w Chapel Hill, NC. Our data showed that the plasma kallikrein – kinin system is involved in the pathogenesis of experimental IBD in genetically susceptible Lewis rats (but not resistant Buffalo or Fisher rat strain) and that a specific inhibitor of this pathway may have a therapeutic potential in IBD (4, 5). Later on published, our results confirmed suggestions indicating that „a single point mutation of serine S11 is responsible for the increased rate of cleavage of high molecular weight kininogen in Lewis rats which is genetically susceptible to inflammatory stimuli: Blood 2003, 102, 2835 – 42. In other project collaborating with my Department of Internal Medicine, Medical University of Silesia, we also documented that the plasma kallikrein – kinin system, coagulation and platelets are activated in human active UC (6). In 1997 I have awarded in Poland received degree of DSc by Polish Scientific Committee (habilitation) in medicine – gastroenterology on the basis of dissertation, "A role of kallikrein – kinin system in the pathogenesis of inflammatory bowel disease”. Since 1997, I investigated a role of intestinal tissue kallikrein – kinin in experimental IBD (7, 8) in n collaboration with Prof. Dr RB Sartor, NC, and Chapel Hill, US. In the recent years I am working as a Associate Professor in the Department of Internal Medicine, and Associate Professor of Dept. of Basic Medical Sciences, doing research and medical practice (two large, prestige research projects founded by Polish Ministry of Sciences) related to a significance of intestinal tissue kallikrein - kinin receptors in the pathogenesis of human IBD and growth factors and angiogenesis in the pathogenesis of human IBD in collaboration with the Department of Molecular Biology and Genetics, Medical University of Silesia.(12- 16), and coagulation study (10, 17). My recent projects were related to the tissue kallikrein – kinin system, and kinin receptors in colorectal polyps as well as a significance of angiogenesis related to kinins and grow factors in ulcerative colitis (15,16). In addition, I have experience to recruit patients with UC to clinical studies and in management and treatment IBD patients.(14). I am a member of Editorial Board of Inflamm Bovel Dis journal, Clinical Section. I was chosen as expert of European Commission to evaluate research IBD projects. In general, I have published mainly as a first author (or co- author) more than 70 full papers (total IF > 100).



Global Speakers in the subject

Global Experts in the subject


Autacoids in Inflammatory Bowel Diseases

Antoni Stadnicki and Izabela Stadnicka
Editorial: J Autacoids 2014, 5: e127
DOI: 10.4172/2161-0479.1000e127